28 Days of Probiotic Milk Eased Dyspepsia Symptoms and Reshaped Gut Bacteria

Up to 30% of adults live with functional dyspepsia, a stubborn disorder that causes postprandial fullness, early satiation, and epigastric pain without any detectable structural cause in the gut. Despite how common it is, no FDA-approved treatments currently exist for the condition, leaving millions of patients cycling through dietary adjustments and off-label medications with mixed results. A new pilot study published in Food Science & Nutrition suggests that a fermented milk beverage containing the probiotic strain Lacticaseibacillus paracasei PC-01 may offer a meaningful, if still preliminary, path forward.

PC-01 Fermented Milk Improved Functional Dyspepsia Symptom Scores

Xi Zhang and colleagues randomized 55 patients diagnosed with functional dyspepsia (FD) into two groups. The experimental group (n=37) drank 200 mL per day of a PC-01 fermented milk beverage containing 5.0 × 10^8 colony-forming units per milliliter. The control group (n=18) received a comparable volume of acidified, non-fermented milk without the probiotic. Both groups continued for 28 days. Symptoms were tracked at baseline, day 14, and day 28 using two validated instruments: the 7-point Global Overall Symptom Scale (GOSS) and the Gastrointestinal Symptom Rating Scale (GSRS).

By the end of the trial, the experimental group showed a statistically higher effective response rate compared to controls (p = 0.04). That is a modest but meaningful signal from a study this size, suggesting the PC-01 strain specifically, rather than the dairy matrix itself, was responsible for some of the benefit. Researchers also collected fecal samples at each time point and ran metagenomic analysis to see whether the symptom changes correlated with shifts in gut microbial communities.

Blautia Enrichment and Clostridium Reduction Point to a Microbial Mechanism

The gut microbiome data offered some of the study's most specific findings. Patients in the experimental group showed enrichment of Blautia, a genus of bacteria broadly associated with gut health benefits including anti-inflammatory properties and production of short-chain fatty acids. At the same time, levels of Clostridium paraputrificum, a potentially pathogenic species, declined in the probiotic group.

Metagenomic pathway analysis revealed that the fatty acid beta-oxidation I pathway (FAO-PWY) was significantly downregulated in the experimental group. The clinical meaning of that specific pathway shift is not yet clear, but it adds mechanistic texture to the symptom data, hinting that PC-01 may alter how gut bacteria process certain fats in ways that affect the intestinal environment.

This is not the first time a Lacticaseibacillus paracasei strain has shown promise against FD. A randomized trial published on Lactobacillus paracasei LC-37 for FD found that a related strain improved dyspepsia symptoms and modulated intestinal microbiota, increasing beneficial bacteria and reducing harmful ones. The PC-01 findings echo that pattern, though the strains are distinct and direct comparisons cannot be drawn.

Why Functional Dyspepsia Remains So Difficult to Treat

Functional dyspepsia affects over 20% of the population worldwide, with a global pooled prevalence estimated at 8.4% when applying strict Rome diagnostic criteria. Women and people in developing countries tend to be disproportionately affected. The disorder significantly degrades quality of life and drives frequent healthcare visits, yet its underlying mechanisms remain contested. Disrupted gut motility, visceral hypersensitivity, altered gut-brain signaling, and microbial imbalance have all been proposed as contributing factors.

The absence of a single clear cause makes treatment difficult. Existing options, including proton pump inhibitors and prokinetic agents, provide incomplete relief for many patients. That gap has pushed researchers toward microbiome-targeted approaches: if dysbiosis contributes to FD symptoms, restoring microbial balance through probiotics or fermented foods may address the disorder more directly than acid suppression alone.

Key Limitations of This Pilot Study

The results are promising, but the study's design has real constraints worth spelling out. The sample was small: 37 patients in the experimental arm and 18 in the control. More importantly, the control beverage was acidified milk rather than a true inert placebo. Acidified dairy products can alter gastric pH and potentially influence gut bacteria in their own right, which means the control condition may not have been fully neutral. That ambiguity complicates the interpretation of between-group differences.

Probiotic clinical trials face well-documented methodological challenges, including high inter-individual variability in the gut microbiome and difficulty designing placebo controls that are genuinely inert. This study is not immune to those problems. The researchers themselves call for larger, multi-center, long-term studies to confirm the findings and establish the safety profile of PC-01 for routine FD management.

What Comes Next for PC-01 and Probiotic FD Research

The 28-day window captures a short slice of what is typically a chronic condition. Whether the microbial shifts observed in this trial persist after the intervention ends, or whether symptom relief is durable, remains unanswered. The study also does not pinpoint which mechanism is doing the most work: is it the PC-01 strain's direct interaction with gut epithelial cells, the secondary changes in microbial community structure, the FAO-PWY pathway downregulation, or some combination?

For patients and clinicians, the takeaway is cautiously encouraging rather than practice-changing. A daily probiotic fermented milk beverage is low-risk and accessible, and this pilot adds to a growing body of evidence that microbiome-targeted strategies may have a legitimate role in managing FD. But the evidence base is still early-stage, and anyone considering probiotic supplementation for chronic digestive symptoms should discuss options with a healthcare provider rather than treating this research as a clinical recommendation. Larger trials with longer follow-up are the necessary next step before PC-01 could be considered a validated FD therapy.

Evidence rating

INVESTIGATIONAL — 78/100

Caveats:

• This was a small pilot RCT (n=55, with only n=18 in the control group), so results are preliminary and not yet sufficient to draw firm conclusions.
• The control beverage was an acidified milk drink, not an inert placebo — it may have had its own effects on gut symptoms and microbiota, making the true size of the probiotic benefit uncertain.
• Funding was not disclosed, so potential conflicts of interest cannot be ruled out.
• Results have not been independently replicated; the authors themselves call for larger, multi-center trials to confirm these findings.

Small randomized controlled pilot trial (n=55) comparing a Lacticaseibacillus paracasei PC-01 fermented milk beverage against an acidified milk control over 28 days. Results show association between the intervention and symptom improvement and gut microbiota shifts, but the non-inert comparator and limited sample size preclude causal conclusions. Findings are consistent with prior work on related Lacticaseibacillus paracasei strains but have not been independently replicated in a larger population.

References

1. Xiangyang Zhang, Erna Sun, Zhixin Zhao, et al. (2026). Intervention With Lacticaseibacillus paracasei PC ‐01 Fermented Milk Beverage Ameliorates Functional Dyspepsia and Modulates Gut Microbiome: A Pilot Study. Food Science & Nutrition. https://doi.org/10.1002/fsn3.71928
2. Jan H. Kleibeuker, Jaap C. Thijs (2004). Functional dyspepsia. Current Opinion in Gastroenterology. https://doi.org/10.1097/00001574-200411000-00007
3. Kyungjae Lee, Hojun Kim, Jing-Hua Wang (2026). Clinical Evidence Linking the Gut Microbiome and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Biomedicines. https://doi.org/10.3390/biomedicines14020457
4. Erna Sun, Xiaomei Zhang, Yifan Zhao, et al. (2021). Beverages containing Lactobacillus paracasei LC-37 improved functional dyspepsia through regulation of the intestinal microbiota and their metabolites. Journal of Dairy Science. https://doi.org/10.3168/jds.2020-19882
5. Functional Dyspepsia – StatPearls – NCBI Bookshelf. NIH. https://www.ncbi.nlm.nih.gov/books/NBK553123/
6. Raul de Jesus Cano, Gissel García Menéndez (2026). Why Clinical Trials of Microbiome-Targeted Interventions Often Fail to Support Health Claims: A Commentary on Probiotics and Translational Design. Microorganisms. https://doi.org/10.3390/microorganisms14020470